Equities
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)13.34
  • Today's Change-0.97 / -6.78%
  • Shares traded10.80m
  • 1 Year change+21.27%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in CNY

The one analyst offering a 12 month price target expects InnoCare Pharma Ltd share price to rise to 16.60 in the next year from the last price of 13.34.
High24.4%16.60
Med24.4%16.60
Low24.4%16.60

Earnings history & estimates in CNY

On Nov 11, 2024, InnoCare Pharma Ltd reported 3rd quarter 2024 losses of -0.01 per share. This result exceeded the -0.09 consensus loss of the one analyst covering the company and exceeded last year's 3rd quarter results by 83.33%.
The next earnings announcement is expected on Mar 30, 2025.
Average growth rate+13.54%
InnoCare Pharma Ltd reported annual 2023 losses of -0.37 per share on Mar 28, 2024.
Average growth rate+38.33%
More ▼

Revenue history & estimates in CNY

InnoCare Pharma Limited had 3rd quarter 2024 revenues of 278.01m. This missed the 288.00m estimate of the one analyst following the company. This was 46.79% above the prior year's 3rd quarter results.
Average growth rate+17.73%
InnoCare Pharma Limited had revenues for the full year 2023 of 738.54m. This was 18.09% above the prior year's results.
Average growth rate+18.09%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.